- Home
- CLLS vs RDIB Comparison
CLLS vs RDIB Comparison
Compare CLLS & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- RDIB
- Stock Information
- Founded
- CLLS 1999
- RDIB 1937
- Country
- CLLS France
- RDIB United States
- Employees
- CLLS N/A
- RDIB N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- RDIB Movies/Entertainment
- Sector
- CLLS Health Care
- RDIB Consumer Discretionary
- Exchange
- CLLS Nasdaq
- RDIB Nasdaq
- Market Cap
- CLLS 299.0M
- RDIB 259.2M
- IPO Year
- CLLS 2007
- RDIB N/A
- Fundamental
- Price
- CLLS $3.22
- RDIB $11.26
- Analyst Decision
- CLLS Buy
- RDIB
- Analyst Count
- CLLS 1
- RDIB 0
- Target Price
- CLLS $8.00
- RDIB N/A
- AVG Volume (30 Days)
- CLLS 134.5K
- RDIB 4.2K
- Earning Date
- CLLS 11-07-2025
- RDIB 11-12-2025
- Dividend Yield
- CLLS N/A
- RDIB N/A
- EPS Growth
- CLLS N/A
- RDIB N/A
- EPS
- CLLS N/A
- RDIB N/A
- Revenue
- CLLS $63,438,000.00
- RDIB $219,213,000.00
- Revenue This Year
- CLLS N/A
- RDIB $6.85
- Revenue Next Year
- CLLS $58.00
- RDIB $10.86
- P/E Ratio
- CLLS N/A
- RDIB N/A
- Revenue Growth
- CLLS 223.09
- RDIB 7.59
- 52 Week Low
- CLLS $1.10
- RDIB $5.78
- 52 Week High
- CLLS $5.48
- RDIB $14.95
- Technical
- Relative Strength Index (RSI)
- CLLS 41.41
- RDIB 47.42
- Support Level
- CLLS $3.12
- RDIB $11.23
- Resistance Level
- CLLS $3.79
- RDIB $12.21
- Average True Range (ATR)
- CLLS 0.19
- RDIB 0.35
- MACD
- CLLS -0.08
- RDIB 0.02
- Stochastic Oscillator
- CLLS 13.43
- RDIB 52.26
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.